Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 99,549
  • Shares Outstanding, K 49,039
  • Annual Sales, $ 0 K
  • Annual Income, $ -27,030 K
  • 60-Month Beta 1.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.13
Trade CRVS with:

Options Overview Details

View History
  • Implied Volatility 126.01% ( +10.76%)
  • Historical Volatility 91.23%
  • IV Percentile 54%
  • IV Rank 26.70%
  • IV High 288.72% on 04/24/24
  • IV Low 66.73% on 09/19/23
  • Put/Call Vol Ratio 0.79
  • Today's Volume 75
  • Volume Avg (30-Day) 82
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 2,477
  • Open Int (30-Day) 2,526

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.14
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.30 +60.00%
on 04/18/24
2.19 -5.02%
on 05/09/24
+0.57 (+37.75%)
since 04/10/24
3-Month
1.30 +60.00%
on 04/18/24
2.45 -15.11%
on 02/27/24
-0.13 (-6.09%)
since 02/09/24
52-Week
1.05 +98.10%
on 10/30/23
4.19 -50.36%
on 06/09/23
+0.37 (+21.64%)
since 05/10/23

Most Recent Stories

More News
Corvus: Q1 Earnings Snapshot

Corvus: Q1 Earnings Snapshot

CRVS : 2.08 (+2.46%)
Corvus: Q4 Earnings Snapshot

Corvus: Q4 Earnings Snapshot

CRVS : 2.08 (+2.46%)
Corvus: Q3 Earnings Snapshot

Corvus: Q3 Earnings Snapshot

CRVS : 2.08 (+2.46%)
Corvus: Q2 Earnings Snapshot

Corvus: Q2 Earnings Snapshot

CRVS : 2.08 (+2.46%)
Corvus: Q1 Earnings Snapshot

Corvus: Q1 Earnings Snapshot

CRVS : 2.08 (+2.46%)
Corvus: Q4 Earnings Snapshot

Corvus: Q4 Earnings Snapshot

CRVS : 2.08 (+2.46%)
Corvus: Q3 Earnings Snapshot

Corvus: Q3 Earnings Snapshot

CRVS : 2.08 (+2.46%)
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

Prioritizing Development of CPI-818 for T Cell Lymphomas, Autoimmune and Allergic Diseases Plans to Begin Phase 2 Clinical Trial of Ciforadenant in...

CRVS : 2.08 (+2.46%)
Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS), a clinical-stage...

CRVS : 2.08 (+2.46%)
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium

Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas Program covers scientific rationale, preclinical...

CRVS : 2.08 (+2.46%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible...

See More

Key Turning Points

3rd Resistance Point 2.46
2nd Resistance Point 2.31
1st Resistance Point 2.20
Last Price 2.08
1st Support Level 1.94
2nd Support Level 1.79
3rd Support Level 1.68

See More

52-Week High 4.19
Fibonacci 61.8% 2.99
Fibonacci 50% 2.62
Fibonacci 38.2% 2.25
Last Price 2.08
52-Week Low 1.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar